Single-cell sequencing technology, applied as a novel drug discovery strategy, significantly enhances the accuracy of antibody drug development. The advantages of this technology include taking immune cells with well-defined biological functions as research & development objects and adopting a reverse discovery process with the capacity of higher-volume information gathering and higher-throughput measurements than conventional antibody discovery technologies, leading to superb precision. This technology can greatly shorten the time dedicated for antibody discovery and also reduce the failure rate of ensuing development. An innovator in drug research & development, Singlomics Biopharmaceuticals has established an independent single-cell high-throughput drug screening and development platform, built on the research work of the academic team directed by our co-founder Dr. Xiaoliang Sunney Xie. Singlomics is using this platform for the rapid reverse research & development of antibody drugs for the treatment of a variety of diseases. For example, we were able to quickly complete reverse screening and development of COVID-19-neutralizing therapeutic antibodies, DXP-593 and DXP-604.

Single-Cell Sequencing Platform

https://doi.org/10.1016/j.cell.2020.05.02